Poster Session 2-2 Hemolytic Anemia

[PS2-2-3] Patient preference for PNH treatment: interim result of patient survey of ravulizumab and eculizumab

Takayuki Ikezoe¹, John Peipert², Austin Kulesekararaj³, Ataulfo Fernandez⁴, Susan Yount², Christa Martens², Amy Sparling², Kimberly Webster², David Cella², Scott Rottinghaus⁵, Bonnie Donato⁵, Ioannis Tomazos⁵, Anna Gaya⁶, Lindsay Mitchell⁷, Anita Hill⁸, Richard Wells⁹, Caroline Piatek¹⁰, Philip Kuriakose¹¹, Irina Murakhovskaya¹², Samer Khaled¹³, Karen Kaiser² (1.Fukushima Medical University, 2.Northwestern University Feinberg School of Medicine, Chicago, USA, 3.Kings College Hospital, London, UK, 4.Hospital Universitario Clinico San Carlos, Spain, 5.Alexion Pharmaceuticals, Inc., New Haven, USA, 6.Hospital Clinic de Barcelona, Spain, 7.University Hospital Monklands, Lanarkshire, Scotland, 8.St James Institute of Oncology, Leeds, UK, 9.Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 10.University of Southern California, Los Angeles, USA, 11.Henry Ford Hospital, Detroit, USA, 12.Montefiore Medical Center, NY, USA, 13.City of Hope, Duarte, USA)